Abstract
The federal government abruptly suspended all U.S.-funded human studies at Johns Hopkins University in Baltimore last week. Then, in a turnabout 3 days later, it allowed about 700 of the more than 2400 that were affected to resume, although with restrictions. The crisis sent a shock through the clinical research world, mainly because Hopkins is regarded as one of the country9s most conscientious overseers of research. And it seemed likely to raise questions anew about how best to protect research subjects.

This publication has 0 references indexed in Scilit: